Table 3 Treatment interruption and treatment outcome in COVID-19-positive and COVID-19-negative patients
Variables | COVID-19-positive patients (25) | COVID-19-negative patients (32) | P value |
|---|---|---|---|
Duration of treatment interruption in COVID-19-positive patients | |||
< 3 weeks | 10 (40.00) | 12 (37.50) | 0.847 |
> 3 weeks | 15 (60.00) | 20 (63.50) | |
Treatment completion in COVID-19-positive patients | |||
Total treatment completed | 15 (60.00) | 26 (81.25) | 0.076 |
Loss to follow-up | 10 (40.00) | 6 (18.75) | |
Treatment outcome in COVID-19-positive patients | |||
Disease clinically controlled | 12 (48.00) | 21 (65.62) | |
Loco-regional progression of disease | 10 (40.00) | 3 (9.37) | |
Developed metastatic diseasea | 2 (8.00) | 1 (3.13) | |
Status unknown | 1 (4.00) | 6 (18.75) | |
Death due to other causeb | 0 (0.00) | 1 (3.13) | |